Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Executive VP-R&D Norbert Bischofberger: An Interview With “The Pink Sheet” DAILY (Part 1 of 3)

This article was originally published in The Pink Sheet Daily

Executive Summary

Exec discusses the therapeutic areas Gilead’s pipeline will focus on in the future, the importance of licensing/acquisition deals and pursuing additional indications for some of the firm’s currently marketed products.

You may also be interested in...



Gilead Executive VP-R&D Norbert Bischofberger: An Interview With “The Pink Sheet” DAILY (Part 2 of 3)

Bischofberger discusses how darusentan could complement recently approved Letairis in the hypertension market, and how Gilead plans to develop its integrase inhibitor elvitegravir, a potential competitor to Merck’s Isentress.

Gilead Executive VP-R&D Norbert Bischofberger: An Interview With “The Pink Sheet” DAILY (Part 2 of 3)

Bischofberger discusses how darusentan could complement recently approved Letairis in the hypertension market, and how Gilead plans to develop its integrase inhibitor elvitegravir, a potential competitor to Merck’s Isentress.

Parion Lands Monster Deal With Gilead For Cystic Fibrosis Candidate

With another CF candidate in Phase III, Gilead looks to build a respiratory disease franchise, R&D chief tells “The Pink Sheet” DAILY.

Related Content

Topics

UsernamePublicRestriction

Register

PS066488

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel